Hardman & Co: Shield Therapeutics (STX): Cash management is key
May 23 2024 - 1:15AM
EQS Non-Regulatory
Hardman & Co Research
Hardman & Co: Shield Therapeutics (STX): Cash management is
key
23-May-2024 / 07:15 GMT/BST
The issuer is solely responsible for the content of this
announcement.
Hardman & Co Research
on Shield Therapeutics (STX):
Cash management is
key
Shield is a
commercial-stage pharma company delivering specialty products that
address patients’ unmet medical needs, with an initial focus on
iron deficiency (ID). Since its US launch in July 2021, Shield and
its partner, Viatris, have increased physician awareness of the
differentiating characteristics of Accrufer® as an oral ID drug, in
order to ramp up prescriptions (Rxs) and generate sales traction.
Positive Rx momentum in 2022 and 2023, is expected to accelerate in
2024 and 2025 with the revised aim of becoming cashflow positive in
2H’25. This, coupled with extended financing options has obviated
any requirement for a capital increase.
Please click on the link
below for the full report:
https://hardmanandco.com/research/corporate-research/stx-cash-management-is-key/
If you are interested in
meeting the company, you can register your interest by clicking on
the above link.
To contact us:
Hardman & Co
9 Bonhill Street
London
EC2A 4DJ
www.hardmanandco.com
Follow us on Twitter
@HardmanandCo
|
Contact:
Dr Martin Hall
|
mh@hardmanandco.com
|
Hardman & Co Research
can still be accessed for free after MiFID II. Please click
here to read the
statement.
About Hardman & Co:
Hardman Research Ltd,
trading as Hardman & Co, is an appointed representative of
Capital Markets Strategy Ltd and is authorised and regulated by the
Financial Conduct Authority; our FCA registration number is 600843.
Hardman Research Ltd is registered at Companies House with number
8256259. Attention is drawn to the important disclaimers at the end
of the report.
Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this
announcement.
|
End of Announcement - EQS News Service
1909175 23-May-2024
Real Estate Credit Inves... (LSE:RECI)
Historical Stock Chart
From May 2024 to Jun 2024
Real Estate Credit Inves... (LSE:RECI)
Historical Stock Chart
From Jun 2023 to Jun 2024